GSK PLC

NYSE: GSK (GSK plc)

最近更新时间: 3天之前, 3:40AM

50.45

0.26 (0.52%)

前收盘价格 50.19
成交量 2,781,491
预期市盈率 (P/E Forward) 10.01
价格/销量 (P/S) 2.30
股市价格/股市净资产 (P/B) 4.09
52周波幅
45.81 (-9%) — 61.70 (22%)
股息率 (DY TTM) 3.66%
营业毛利率 10.00%
营业利益率 (TTM) 30.79%
稀释每股收益 (EPS TTM) 2.07
季度收入增长率 (YOY) 2.10%
季度盈利增长率 (YOY) 55.30%
总债务/股东权益 (D/E MRQ) 134.99%
流动比率 (MRQ) 0.870
营业现金流 (OCF TTM) 6.74 B
杠杆自由现金流 (LFCF TTM) 5.16 B
资产报酬率 (ROA TTM) 6.55%
股东权益报酬率 (ROE TTM) 27.09%

AIStockmoo 评分

-0.3
价值 30% -0.5
来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 NA
相对估值 参考 NA
当前股价隐含每年 8.5% 的盈利增长;公司业务可支撑约每年 5.4% 的增长。 参考
历史估值 参考 NA
负债高。盈利能力强。短期流动性偏紧。现金流为正。 参考
资本回报 参考 NA
时机 30% -0.1
来自我们对走势图的 AI 技术分析。 参考 NA
过去一年没有明确趋势。股价略低于52周高点。 参考
K线形态 参考 NA
您持有期的趋势 参考 NA
市场情绪 20% 0.9
近期没有目标价,因此依据目标价的调整方向。 参考
近期新闻大多正面。 参考
聪明钱 20% -1.6
内部交易活动 参考 NA
机构在最新13F申报中净-1.01%的股份:492家增持,453家减持(截至30 Sep 2026的季度)。 参考
市场和行业状况中性。
市场环境偏谨慎。 参考
行业表现优于大市。
各支柱方向不一,评分因此减弱。
不计入评分
股价接近其52周平均水平。5年来上涨。 参考
短、中、长期趋势均向上。短期动能上升。 参考
股价处于支撑位与阻力位之间。支撑与阻力水平趋升。 参考
最终评分 -0.32

市场趋势

短期 中期
行业 Drug Manufacturers - General (US) 混合的 看涨
Drug Manufacturers - General (全球的) 混合的 看涨
股票 GSK plc 混合的 混合的

相关股票

股票 市值 DY P/E(TTM) P/B
GSK - 3.66% - 4.09
JNJ - 1.92% - 8.44
PFE - 6.00% - 1.85
ABBV - 3.18% - -
NVO - 4.16% - 5.56
BMY - 4.36% - 5.54

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

部门 Healthcare
行业 Drug Manufacturers - General
投资方式 Large Value
内部持股比例 0.06%
机构持股比例 18.28%

所有权

姓名 日期 持有股份
Jtc Employer Solutions Trustee Ltd 30 Sep 2026 8,077,477

该时间范围内无数据。

该时间范围内无数据。

机构

机构持股比例: 16.68%

持仓变动 机构数 股数
增持 492 12,542,199
减持 453 30,916,019
新建仓 97 6,592,096
清仓 112 8,607,137

来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。

8 正面 0 负面 2 中性
日期 类型 细节
12 Nov 2026 Yahoo Finance GSK (LSE:GSK) Settles Key Vaccine Patent Case And Wins Broad Europe Injunction
GSK (LSE:GSK) reached a cross-licensing agreement with Moderna resolving their COVID-19 vaccine patent dispute in Europe. The pharma group secured a significant injunction against Pfizer-BioNTech covering liposome delivery technology used in RNA vaccines across multiple European markets. Ongoing…
12 Nov 2026 Yahoo Finance Is GSK (LSE:GSK) A Bargain Following Its New Alamar Collaboration?
How GSK’s new Alamar collaboration reshapes the research story GSK (LSE:GSK) just linked up with Alamar Biosciences on a large proteomics study that aims to match circulating protein patterns with how complex diseases develop and respond to treatment. The project leans on Alamar’s NULISA platform…
09 Nov 2026 Yahoo Finance What GSK (LSE:GSK)'s Cancer And HIV Trial Wins Mean For Shareholders
GSK has recently reported multiple clinical updates, including strong phase II rectal cancer data for Jemperli, durable phase I responses for Mo Rez in ovarian and endometrial cancers, and real world adherence benefits from ViiV Healthcare’s long acting HIV regimen. Together, these oncology and HIV…
09 Nov 2026 Yahoo Finance Why Is GSK (LSE:GSK) Drawing Attention For New Cancer Data And Proteomics?
GSK (LSE:GSK) agreed a major scientific collaboration with Alamar Biosciences to run large-scale proteomic research for precision medicine. New clinical data showed highly encouraging results for Jemperli in rectal cancer patients in an ongoing oncology study. Mo-Rez produced promising trial…
09 Nov 2026 Yahoo Finance GSK Accelerates Late-Stage Studies as It Targets COPD and Long-Acting Respiratory Treatments
GSK (NYSE:GSK) is advancing a portfolio of long-acting medicines and combination treatments for respiratory and inflammatory diseases, with a particular focus on chronic obstructive pulmonary disease, a senior research executive said at Guggenheim’s Healthcare Innovation Conference. Kaivan Khavandi…
09 Nov 2026 Yahoo Finance Vocabria + Rekambys associated with greater adherence versus daily oral therapy in a US real-world study, as ViiV Healthcare presents broader long-acting portfolio and pipeline data at HIV Glasgow
LONDON, November 09, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced data to be presented at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow). It marks ViiV Healthcare’s largest congress…
06 Nov 2026 Yahoo Finance GSK (LSE:GSK) Stock Still Looks Below Fair Value Following Jemperli Approval
GSK plc has delivered strong multi year gains for shareholders, and the latest news around its cancer and specialty medicines raises a straightforward question for you as an investor. Is the current share price near £18.90 adequately supported by the drug maker's earnings power, or has sentiment…
05 Nov 2026 Yahoo Finance ViiV Healthcare Commits $100 Million to Build More Resilient Local HIV Care Networks Across the United States
DURHAM, N.C., November 05, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced a $100 million, three-year commitment through its U.S. Positive Action program, to provide sustained support to community organizations…
03 Nov 2026 Yahoo Finance Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine
Alamar’s NULISAseq™ Immune 340 and NULISAseq™ Neuro 220 panels will be used to investigate disease progression, biological subtypes and treatment responseFREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to…
01 Nov 2026 Yahoo Finance GSK (LSE:GSK) Wins FDA Nod For Jemperli As ESMO Data Builds Oncology Case
GSK (LSE:GSK) received accelerated FDA approval for Jemperli as the first immunotherapy for certain rectal cancer patients. The approval covers a genetically defined group of rectal cancer cases where Jemperli offers a non surgical treatment option. GSK presented updated data for Mo-Rez in ovarian…
29 Oct 2026 Yahoo Finance GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?
GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.
29 Oct 2026 Yahoo Finance Chiesi Group appoints Paolo Paoletti to its Board of Directors
PARMA, Italy, October 29, 2026--Chiesi, the international research-focused biopharmaceutical group, today announced the appointment of Paolo Paoletti, M.D. to its Board of Directors, effective as of today. Paoletti is an internationally recognized pharmaceutical executive with more than 30 years of…
29 Oct 2026 Yahoo Finance GSK (LSE:GSK) Shares Dropped, So What Is Behind The Latest Attention?
GSK (LSE:GSK) has released third quarter figures that present a mixed picture. Sales reached £8,887 million, while net income declined to £1,543 million compared with £2,013 million a year earlier. The latest figures landed alongside a sharp market reaction, with GSK’s 1-day share price return…
28 Oct 2026 Yahoo Finance Genmab Stock Surges to Record High After Stunning Cancer Drug Results
Genmab scores a ‘hat trick’ with positive data for its experimental cancer drug, petosemtamab, Jefferies says.
28 Oct 2026 Yahoo Finance Glaxo: Q3 Earnings Snapshot
LONDON (AP) — LONDON (AP) — GSK plc (GSK) on Wednesday reported third-quarter net income of $2.On a per-share basis, the London-based company said it had net income of $1…
28 Oct 2026 Yahoo Finance What GSK (GSK) Said on Its Q3 Earnings Call
GSK (NYSE:GSK) reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, supported by specialty medicines, new product launches and oncology growth. Core operating profit increased 5%, while core earnings per share rose 1%. The company reconfirmed its 2026 guidance, with…
显示更多
股息率 (DY TTM) 3.66%
4年平均股息收益率 2.51%
股息支付比率 80.20%
除息日 公告日期 支付日期 详情
15 Nov 2024 30 Oct 2024 09 Jan 2025 0.389052 现金
16 Aug 2024 31 Jul 2024 10 Oct 2024 0.385671 现金
16 May 2024 01 May 2024 11 Jul 2024 0.376185 现金
22 Feb 2024 01 Feb 2024 11 Apr 2024 0.4060608 现金
16 Nov 2023 01 Nov 2023 11 Jan 2024 0.3397772 现金
17 Aug 2023 26 Jul 2023 12 Oct 2023 0.361256 现金
18 May 2023 26 Apr 2023 13 Jul 2023 0.347508 现金
23 Feb 2023 01 Feb 2023 13 Apr 2023 0.3403867 现金
17 Nov 2022 02 Nov 2022 12 Jan 2023 0.3171217 现金
18 Aug 2022 27 Jul 2022 06 Oct 2022 0.390832 现金

每年股息收益率

年份 每年总股息 ($) 频率/年份 收益率 %
2025 0.389 1 0.79
2024 1.51 4 4.46
2023 1.37 4 3.69
2022 0.391 1 1.11

近期信号 K线形态与EMA交叉

▲ EMA看涨交叉 4个交易日前 · 09 Nov
中期 · EMA 20/50
20日EMA上穿50日EMA:中期趋势转为向上。
▲ 黄金交叉 2个交易日前 · 11 Nov
长期 · EMA 50/200
50日EMA上穿200日EMA,是广受关注的长期趋势转为向上的信号。

AI 技术分析

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票